Basel Medical Group Ltd BMGL
5.34 USD +0.13 (+2.49%)
Nov 4, 2026, 12:45 PM EST
5.23 Day range 5.49
2.56 52-week range 18.48
- YTD
- -9.19%
- 1 year
- -69.31%
Financial health
Altman Z-Score
1.30 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 3
Valuation
P/E -18.7×
FY 2021 5y median 47.2× FY 2025
P/S 0.4×
FY 2021 5y median 9.4× FY 2025
P/B 1.7×
FY 2021 5y median 12.9× FY 2025
P/FCF -9.8×
FY 2021 5y median 37.1× FY 2025
EV/EBITDA -40.3×
FY 2021 5y median 32.2× FY 2025
EV/Sales 0.8×
FY 2021 5y median 10.0× FY 2025
FCF Yield -10.2%
FY 2021 5y median 2.6% FY 2025
Profitability
Gross Margin 38.8%
FY 2021 5y median 77.6% FY 2025
Operating Margin 38.7%
FY 2021 5y median 21.8% FY 2025
Net Margin -3.5%
FY 2021 5y median 18.4% FY 2025
ROE -14.8%
FY 2021 5y median 27.4% FY 2025
ROIC 58.9%
FY 2021 5y median 14.8% FY 2025
ROA -4.2%
FY 2021 5y median 11.6% FY 2025
Growth (YoY)
Revenue 90.0%
FY 2021 FY 2025
Operating Income 481.7%
FY 2021 FY 2025
EPS (diluted) 93.1%
FY 2021 FY 2025
Free Cash Flow 79.9%
FY 2021 FY 2025
Financial Health
Current Ratio 1.2×
FY 2021 5y median 2.2× FY 2025
Quick Ratio 1.2×
FY 2021 5y median 2.2× FY 2025
Debt / Equity 1.9×
FY 2021 5y median 1.3× FY 2025
Net Debt / EBITDA -20.7×
FY 2021 5y median 0.8× FY 2025
Interest Coverage 18.1×
FY 2021 5y median 8.4× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2026-06-30